Skip to main content
Equibles

GDTC · CytoMed Therapeutics Ltd · Financials

Track GDTC — free

Use GDTC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GDTC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.87 +0.02 (+2.28%)
Rebalance outlook locked
Market Cap
$10.17M
Shares
11.93M
Volume · Oct 20 8282 Avg daily vol (3M) 81.1K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Revenue
324.39K +366.7%
FY2025 Revenue FY2021–FY2025
Net Income
-3.98M -58.2%
FY2025 Net Income FY2020–FY2025
Diluted EPS
-0.34 -54.5%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
-3.7M -36.4%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2025 FY2024 FY2023 FY2022
USD/shares -$0.27 -$0.16 -$0.29 —
USD/shares -$0.27 -$0.16 -$0.29 -$0.30
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Borrowings 2025-12-31 SGD 409,503 20-F filed 2026-03-31
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Noncurrent long-term borrowings
SGD 368,656
Short-term borrowings
SGD 40,847
Current lease liabilities 2025-12-31 USD 15,241 20-F filed 2026-03-31
Lease liabilities 2025-12-31 SGD 73,059 20-F filed 2026-03-31
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current lease liabilities
SGD 19,598
Noncurrent lease liabilities
SGD 53,461
Noncurrent lease liabilities 2025-12-31 USD 41,575 20-F filed 2026-03-31
Noncurrent long-term borrowings 2025-12-31 USD 286,691 20-F filed 2026-03-31
Secured bank loans received 2025-12-31 SGD 409,503 20-F filed 2026-03-31
Short-term borrowings 2025-12-31 USD 31,765 20-F filed 2026-03-31
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1873093 CUSIP Y1R80M106 Visit website Investor relations